Apogee Therapeutics, Inc. (APGE)
- Previous Close
49.77 - Open
49.37 - Bid 49.42 x 200
- Ask --
- Day's Range
49.37 - 50.48 - 52 Week Range
14.19 - 72.29 - Volume
11,386 - Avg. Volume
708,214 - Market Cap (intraday)
2.932B - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
85.80
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.
www.apogeetherapeutics.comRecent News: APGE
Performance Overview: APGE
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: APGE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: APGE
Valuation Measures
Market Cap
2.91B
Enterprise Value
2.52B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
5.78
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-29.95
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-21.00%
Return on Equity (ttm)
-32.18%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-83.98M
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
395.46M
Total Debt/Equity (mrq)
0.54%
Levered Free Cash Flow (ttm)
-45.5M